Monoclonal antibody
Type Whole antibody
Source Human
Target PDGF-R α
Clinical data
ATC code none
Legal status
Legal status
  • investigational
CAS Number 1024603-93-7 N
ChemSpider none
KEGG D09939 N
Chemical and physical data
Formula C6554H10076N1736O2048S40
Molar mass 147.2 kg/mol
 NYesY (what is this?)  (verify)

Olaratumab is a monoclonal antibody which is being developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.[1]

In February 2015, the European Medicines Agency assigned olaratumab orphan drug status for the treatment of soft tissue sarcoma.[2] In October 2016, the FDA issued an approval notice for use of olaratumab with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS).[3]


  1. Statement on a Nonproprietary name adopted by the USAN Council: Olaratumab
  2. Orphan Medicinal Products Designation
  3. FDA grants accelerated approval to new treatment for advanced soft tissue sarcoma October 19, 2016
This article is issued from Wikipedia - version of the 10/21/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.